Lumentin®44 – A new standard in small bowel imaging
The first and only peroral agent to provide perfect negative contrast with CT imaging.
Breaking news:
Lument signs Letter of Intent with GE.
Lumentin®44 food-based contrast agent provides CT images with MRI quality.
Lumentin® is a per-oral HU*-negative contrast agent that allows the small bowel void to be displayed in black against the mucosa, which is displayed in white. For the first time, MRI-quality images can be obtained by using the faster and cheaper CT imaging technology. The images below show the difference in contrast between Lumentin®44 and today’s dominating contrast agents.
Lumentin
Negative contrast
The black background provided by Lumentin highlights the bowel wall and mucosal lining in bright contrast
Moviprep Neutral contrast agent
Omnipaque Positive contrast
The black background provided by Lumentin highlights the bowel wall and mucosal lining in bright contrast
Extracting brilliance from air
It´s a well-known fact among radiologists that air provides perfect negative contrast. This is utilized in imaging the colon, which is relatively easy to fill up with air. However, introducing air into the small intestine is much more complex. Our solution is a patented, drinkable, food-based foam, primarily consisting of egg white and water, where air bubbles of a specific size remain stable as the foam passes through the stomach and fills up the small intestine to the last part. Lumentin®44 and the dispenser used for its preparation result from more than a decade of advanced R&D involving expertise in radiology, gastroenterology, food technology, physical chemistry, and medical device engineering.
Lumentin®44 means enhanced efficacy and elevated patient acceptance
Lumentin is conveniently delivered in powder portions and prepared at the clinic
Improves diagnostic quality
Lumentin®44 provides outstanding contrast,
facilitating both the demarcation of the small intestine and the detection of lesions in the bowel wall.
Saves time and resources
Lumentin®44 enables using a CT scanner instead of the considerably more expensive and time-consuming MRI technology. Time savings are at least 50 percent during the examination itself.
Gentle to the patient
Lumentin®44 is food-based, has good palatability, and a high safety profile. Allowing examinations that previously required MRI to be conducted in a CT scanner avoids much discomfort for the patient.
Increases accessibility
CT scanners are much more common and available at more healthcare facilities than MRI units, making examinations and diagnostics more
accessible, thus facilitating early diagnosis.
Easy to prepare
Lumentin®44 comes as a powder in a pouch and is mixed with water to a drinkable foam at the clinic using a semi-automatic preparation unit. Preparation is ready in minutes.
1 of 3
Krävs plugin eller js
“With this kind of technology, we’ll have a great potential to find small bowel abnormalities much quicker and easier and with less hassle for the patient”
Judy Yee
MD, PhD, Radiologist, USA
1 of 3
“With this kind of technology, we’ll have a great potential to find small bowel abnormalities much quicker and easier and with less hassle for the patient”
Judy Yee
MD, PhD, Radiologist, USA
2 of 3
“With this kind of technology, we’ll have a great potential to find small bowel abnormalities much quicker and easier and with less hassle for the patient”
Judy Yee
MD, PhD, Radiologist, USA
3 of 3
“With this kind of technology, we’ll have a great potential to find small bowel abnormalities much quicker and easier and with less hassle for the patient”
Judy Yee
MD, PhD, Radiologist, USA
Lumentin® 44 Reconstitution Device
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
International advisory board formed by top experts
Our international advisory board represents immense knowledge and experience in radiology and adjacent areas. It serves as an invaluable sounding board in our development work and the planning and evaluation of clinical studies. Through our advisory board, we also gain access to a highly qualified global network.
Lumentin®44 means enhanced efficacy and elevated patient acceptance
Improves diagnostic quality
Idque Caesaris facere voluntate liceret: sese habere. Ambitioni dedisse scripsisse iudicaretur. Ullamco laboris nisi ut aliquid ex ea commodi consequat. Inmensae subtilitatis, obscuris et malesuada fames.
Saves time and resources
Idque Caesaris facere voluntate liceret: sese habere. Ambitioni dedisse scripsisse iudicaretur. Ullamco laboris nisi ut aliquid ex ea commodi consequat. Inmensae subtilitatis, obscuris et malesuada fames.
Gentle to the patient
Idque Caesaris facere voluntate liceret: sese habere. Ambitioni dedisse scripsisse iudicaretur. Ullamco laboris nisi ut aliquid ex ea commodi consequat. Inmensae subtilitatis, obscuris et malesuada fames.
Increases accessibility
Idque Caesaris facere voluntate liceret: sese habere. Ambitioni dedisse scripsisse iudicaretur. Ullamco laboris nisi ut aliquid ex ea commodi consequat. Inmensae subtilitatis, obscuris et malesuada fames.
Easy to prepare
Idque Caesaris facere voluntate liceret: sese habere. Ambitioni dedisse scripsisse iudicaretur. Ullamco laboris nisi ut aliquid ex ea commodi consequat. Inmensae subtilitatis, obscuris et malesuada fames.
Lumentin®44 means enhanced efficacy and elevated patient acceptance
Lumentin is conveniently delivered in powder portions and prepared at the clinic
Virtual endoscopy
The Lumentin® 3-D software gives the radiologist access to a “virtual endoscopy” in high resolution.
AI Powered
Launch of AI project to achieve faster and more accurate interpretation of CT-scan results by leveraging unmatched CT-image quality.
Lumentin®44 means enhanced efficacy and elevated patient acceptance
The mission
Enable CT-images of unique clarity for early and accurate diagnostics by using a truly HU-negative per-oral contrast agent
The vision
Become the market leader in food-based solutions for medical imaging of the abdomen.
Lumentin®44 means enhanced efficacy and elevated patient acceptance
Lumentin is conveniently delivered in powder portions and prepared at the clinic
Portion Pouch
Lumentin® 44 contrast agent is conveniently delivered as a powder packed in portion-pouches.
Drinkable Foam
The powder is freshly prepared into a drinkable foam by the Lumentin® 44 reconstitution device.
CT-Scan
After drinking the contrast agent, the patient is examined in the CT-scanner
High Contrast Images
Images show the small intestine in perfect contrast. Its mucous membrane stands out in clarity due to the black content of the bowel
Lumentin®44 means enhanced efficacy and elevated patient acceptance
Improves diagnostic quality
Idque Caesaris facere voluntate liceret: sese habere. Ambitioni dedisse scripsisse iudicaretur. Ullamco laboris nisi ut aliquid ex ea commodi consequat. Inmensae subtilitatis, obscuris et malesuada fames.
Saves time and resources
Idque Caesaris facere voluntate liceret: sese habere. Ambitioni dedisse scripsisse iudicaretur. Ullamco laboris nisi ut aliquid ex ea commodi consequat. Inmensae subtilitatis, obscuris et malesuada fames.
Gentle to the patient
Idque Caesaris facere voluntate liceret: sese habere. Ambitioni dedisse scripsisse iudicaretur. Ullamco laboris nisi ut aliquid ex ea commodi consequat. Inmensae subtilitatis, obscuris et malesuada fames.
Increases accessibility
Idque Caesaris facere voluntate liceret: sese habere. Ambitioni dedisse scripsisse iudicaretur. Ullamco laboris nisi ut aliquid ex ea commodi consequat. Inmensae subtilitatis, obscuris et malesuada fames.
Easy to prepare
Idque Caesaris facere voluntate liceret: sese habere. Ambitioni dedisse scripsisse iudicaretur. Ullamco laboris nisi ut aliquid ex ea commodi consequat. Inmensae subtilitatis, obscuris et malesuada fames.
It all started with an unexpected discovery…
In 2006, the two radiologists Thomas Fork and Ingvar Adnerhill discovered the potential to use liquid oat cream as a food-based negative contrast agent
Thomas Fork had brought up the idea of developing a true HU-negative bowel contrast agent for computed tomography (CT) that mimics the T1-weighted MRI image of a Gadolindium-enhanced small bowel. The novelty of the product was also to be food-based, pleasant to drink, and with no side effects. Thomas Fork and Ingvar Adnerhill contacted professor Rickard Öste (founder of Oatly) in 2006 to discuss the potential capability of Oatly cream to become the first HU-negative oral contrast agent due to its content in fat.
Rickard Öste, together with Björn Bergenståhl, a professor in Physical Chemistry, agreed to set up a collaboration, and founded Lument AB together with the two radiologists in 2006. This marked the start of a nearly two-decade-long development project involving a multidisciplinary team of experts and scientists.
People
Management
Jan Marsal
MD, PhD, CMO
jan.marsal@lumentab.com
Board of directors
Thomas Fork
MD, PhD, Senior Consultant Radiologist, Co-founder
Ingvar Adnerhill
MD, Senior Consultant Radiologist, Co-founder
Rickard Öste
PhD, Professor, Bord Director, Co-founder & Owner
Björn Öste
Board Director & Owner
Rolf Bjerndell
Chairman of the Board
Peter Leander
MD, PhD, Senior Consultant Radiologist, Clinical Strategy, Co-opted member
Our advisory board
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lumentin® Science
- Hounsfield units (HU) standardize grayscale in CT scans for easier interpretation
- In X-ray imaging, low-density materials like air appear black due to minimal X-ray absorption
- Increased darkness in the image enhances the detection of density differences, aiding in the identification of anatomical structures or abnormalities
Lumentin acts like air, enhancing imaging by separating the small intestines from other organs for improved diagnostics
It´s a well-known fact among radiologists that air provides perfect negative contrast. This is utilized in imaging the colon, which is relatively easy to fill up with air. However, introducing air into the small intestine is much more complex. Our solution is a patented, drinkable, food-based foam, primarily consisting of egg white and water, where air bubbles of a specific size remain stable as the foam passes through the stomach and fills up the small intestine to the last part. Lumentin®44 and the dispenser used for its preparation result from more than a decade of advanced R&D involving expertise in radiology, gastroenterology, food technology, physical chemistry, and medical device engineering.
Proven in clinical trials
Lumentin®44 has been proven in Phase 1 and two Phase 2 clinical trials. A Phase 3 multicenter clinical study in the EU and US is planned to be finalized in 2027.
| Phase 1 2016 | Phase 2a 2017-2018 | Phase 2b 2020-2022 | Phase 3 2024-2027 | |
|---|---|---|---|---|
| Key take-aways | Successfully filled the small intestine with negative contrast Easily consumable, exhibited no significant side effects | Comparison between Lumentin, Omnipaque and MoviePrep Superior performance compared to leading CT contrast agents | CTE1 with Lumentin vs MRE2 – blind test with radiologists CT with Lumentin equally good or better than MRE in 88% of cases | Demonstrate Lumentin’s superiority over Omnipaque This time at a greater scale in both Europe and the US |
| Patients | 25 healthy volunteers compared with 50 historical controls | 45 oncological volunteers with no anomalies, no bowel symptons, remitted to CT-scan | 60 Crohn’s disease patients | Multicenter trials 300-400 patients |
| Imaging | CT-scan | CT-scan | CT-scan and MRE | CT-scan |
| IMP | Lumentin (60% v/v air content) | Lumentin, Moviprep, Omnipaque | Lumentin for CTE; Moviprep for MRE | Lumentin, Opaque |
| IV3 Contrast agent | None (Iodine contrast Omnipaque 350 mg l/mL was not used) | Iodine contrast (Omnipaque 350 mg l/mL) | Iodine contrast (Omnipaque 350 mg l/mL for CTE; Gadolinium for MRE) | Iodine contrast (Omnipaque 350 mg l/mL) |
| Phase 1 2016 | Phase 2a 2017-2018 | Phase 2b 2020-2022 | Phase 3 2024-2027 | |
|---|---|---|---|---|
| Key take-aways | Successfully filled the small intestine with negative contrast Easily consumable, exhibited no significant side effects | Comparison between Lumentin, Omnipaque and MoviePrep Superior performance compared to leading CT contrast agents | CTE1 with Lumentin vs MRE2 – blind test with radiologists CT with Lumentin equally good or better than MRE in 88% of cases | Demonstrate Lumentin’s superiority over Omnipaque This time at a greater scale in both Europe and the US |
| Patients | 25 healthy volunteers compared with 50 historical controls | 45 oncological volunteers with no anomalies, no bowel symptons, remitted to CT-scan | 60 Crohn’s disease patients | Multicenter trials 300-400 patients |
| Imaging | CT-scan | CT-scan | CT-scan and MRE | CT-scan |
| IMP | Lumentin (60% v/v air content) | Lumentin, Moviprep, Omnipaque | Lumentin for CTE; Moviprep for MRE | Lumentin, Opaque |
| IV3 Contrast agent | None (Iodine contrast Omnipaque 350 mg l/mL was not used) | Iodine contrast (Omnipaque 350 mg l/mL) | Iodine contrast (Omnipaque 350 mg l/mL for CTE; Gadolinium for MRE) | Iodine contrast (Omnipaque 350 mg l/mL) |
“The images are spectacular, and it was interesting that the gastroenterologists found the CT with Lumentin in general clinically more useful than the MRI.”
Giles Stevenson
MD, PhD, Radiologist, Canada)
The Hounsfield scale is used to standardize the grayscale in CT-scans for easier interpretation. While bone appears in white, air represents the other end of the scale, appearing in negative/black contrast.
The Hounsfield scale is used to standardize the grayscale in CT-scans for easier interpretation. While bone appears in white, air represents the other end of the scale, appearing in negative/black contrast.
Lorem Ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lument AB
Scheelevägen 22
Box 719
223 63 Lund
Phone +46 46 16 39 40
Email info@lumentab.com
Lument is part of the Aventure Group
www.aventureab.com
Send us a message
References
- ACR–SPR (2016)
Practice parameter for the performance of computed tomography (CT) of the abdomen and computed tomography (CT) of the pelvis.
https://www.acr.org/-/media/ACR/Files/Practice-Parameters/ct-abd-pel.pdf. Revised 2021
- Basile J, Kenny JF, Khodorkovsky B, et al (2018)
Effects of eliminating routine use of oral contrast for computed tomography of the abdomen and pelvis: a pilot study.
Clin Imaging 49:159–162. https://doi.org/10.1016/j.clinimag.2018.03.002
- Taylor MB, Bromham NR, Arnold SE (2012)
Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines.
Br J Radiol 85:661–671. https://doi.org/10.1259/bjr/75018360
- Pickhardt PJ (2020)
Positive oral contrast material for abdominal CT: current clinical indications and areas of controversy.
AJR Am J Roentgenol 215:69–78. https://doi.org/10.2214/AJR.19.21989
- Fork FT, Aabakken L (2007)
Capsule enteroscopy and radiology of the small intestine.
Eur Radiol 17:3103–3111. 10.1007/s00330-007-0718-766.
- Fork FT, Karlsson N, Kadhem S, Ohlsson B (2012)
Small bowel enteroclyses with magnetic resonance imaging and computed tomography in patients with failed and uncertained passage of a patency capsule.
BMC Med Imaging Feb 12:3. https://doi.org/10.1186/1471-2342-12-3.
- Megibow AJ, Babb JS, Hecht EM, et al (2006) Evaluation of bowel distention and bowel wall appearance by using neutral oral contrast agent for multi-detector row CT. Radiology 238:87–95. https://doi.org/10.1148/radiol.2381041985
“>Scientific Advice Meetings
Already held in Q1-Q2 2022:
- MHRA, March 2022
- BfArM, June 2022
- FDA, June 2022
Already held in Q1-Q2 2022:
- MHRA, March 2022
- BfArM, June 2022
- FDA, June 2022
Articles
Lumentin®44 has triumphed in its ability to produce razor-sharp images with MRI-quality contrast, all while ensuring minimal discomfort for the patient. This success has been demonstrated in our phase I, phase IIA, and phase IIB clinical studies. As we look ahead, a phase 3 multicenter study is set to commence at the end of 2024, marking another significant milestone in our journey.
